SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The Sperm Whale is drawing intense attention as a highly volatile meme coin, with the community actively debating whether it is a legitimate high-reward opportunity or a classic pump-and-dump scheme. Investors are closely monitoring its price action and social media momentum, with some hoping for a massive rebound while others warn of the inherent risks of unverified, rapid-fluctuation tokens.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant community debate as investors weigh the project's institutional privacy ambitions against concerns regarding centralized infrastructure and potential regulatory hurdles. While some holders are actively accumulating amid volatility and anticipating mainnet milestones, others express skepticism regarding leadership and the overall rollout strategy.

$FUUU is a Solana-based memecoin that was launched on http://Pump.fun in March 2024. The project is themed around the Rage Guy character, a figure that originated in the rage comic era of the late 2000s and became widely recognized across internet culture. Following the launch, the original developer discontinued involvement with the token. At that point, the CTO team assumed responsibility for coordinating ongoing community efforts around the project.  The stated purpose of $FUUU is cultural rather than financial. It is designed as a “culture coin” that highlights Rage Guy as a symbolic and relatable figure. The character’s expression of frustration, commonly represented by the text “FFFFUUUU,” reflects emotions that are often tied to both cryptocurrency markets and everyday experiences. By building a token around this meme, the project aims to preserve a recognizable piece of internet history within a blockchain context.  Unlike projects that emphasize detailed roadmaps, technical milestones, or defined utility, $FUUU positions itself as a lighthearted and entertainment-driven token. There are no team allocations, no taxes, and no embedded promises of profit or financial return. The coin is intended solely for cultural engagement, community participation, and meme creation. Holders and community members are encouraged to contribute through content, discussion, and the continued use of Rage Guy imagery, but there are no obligations or formal expectations tied to the token.  The CTO team provides organizational support, and back end support such as hiring an artist and creatin websites, the community drives activity associated with the project. This includes creating and sharing memes, maintaining discussion channels, and ensuring the Rage Guy character remains present in contemporary internet culture. The project does not claim utility beyond its role as a culture coin, and its sustainability depends entirely on voluntary participation and ongoing community interest.  From a transparency standpoint, the on-chain parameters of the token are publicly visible. These include the mint authority status, freeze authority, liquidity details (whether burned or locked), and circulating supply information. Any locked or burn addresses are disclosed for the purpose of supporting accurate supply tracking on external platforms.  Rage Guy ($FUUU) should not be viewed as an investment. The token has no intrinsic value and provides no rights, revenue, or guarantees to holders. As with all cryptoassets, trading is highly risky, and participants are advised to conduct their own research and fully understand the risks involved. The project’s focus remains cultural preservation and community expression rather than financial

FUUUUUUUUUUUUUU

FUUU is trending as retail investors rally behind the meme coin, viewing it as a symbolic expression of market frustration and a high-risk opportunity for potential gains. While some community members aggressively push for price catalysts and zero-burning, others debate its long-term legitimacy, with discussions centered on its viral volatility and speculative nature.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members highlight its role in fueling player economies within blockchain games, fueling speculation about a potential reversal and a rally toward higher price targets. Investors are actively discussing the token's long-term utility in Web3 gaming and monitoring key breakout levels as sentiment remains bullish.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Celldex Therapeutics is trending as investors monitor ongoing Phase 3 trials and anticipation for multiple upcoming clinical data readouts. The community is actively debating the company's long-term valuation against potential competitive therapies and the strategic direction of its mast cell-targeted pipeline.

ARK ETF Trust - ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF

The ARK Space Exploration & Innovation ETF continues to generate active debate as investors rotate between long-term optimism for the space economy and frustration over the fund's recent performance. The community is heavily focused on the integration of AI in space defense, the potential for future SpaceX exposure, and the strategic positioning of core holdings like Rocket Lab.

Direxion Shares ETF Trust - Direxion Daily FTSE China Bear 3X ETF

Direxion Daily FTSE China Bear 3X Shares

YANG is trending as investors weigh China's aggressive stimulus measures and market-wide rallies against the lingering threat of escalating trade tensions and potential US tariff actions. The community is actively debating whether to capitalize on the recent Chinese equity breakout or prepare for a sharp reversal as market participants closely monitor the sustainability of the current rally amidst persistent macroeconomic skepticism.

Nova Ltd. provides metrology solutions for the semiconductor manufacturing industry. Its product portfolio includes dimensional metrology, modeling & software, materials metrology, and chemical metrology. The company was founded by Giora Dishon and Moshe Finarov in May 1993 and is headquartered in Rehovot, Israel.

Nova Ltd

Nova Ltd is capturing investor interest as a key player in the semiconductor capital expenditure cycle, with the community highlighting its strong position in AI-driven chip infrastructure and advanced metrology. Recent bullish analyst coverage and optimism surrounding its earnings trajectory are fueling active discussions about the stock's long-term growth potential and momentum.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF is trending as investors weigh conflicting indicators, including a strong trade surplus and ongoing tech-sector policy shifts against persistent concerns over a property-sector downturn and complex geopolitical relations. Community discourse is heavily focused on whether recent stimulus signals represent a sustainable economic pivot or a temporary relief rally amidst a long-standing environment of volatility and structural uncertainty.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is capturing investor attention as a key infrastructure player in the nuclear sector, bolstered by significant government defense contracts and an expanding role in the commercial SMR market. The community is actively debating its growth potential relative to smaller nuclear startups, with many viewing it as a safer, established 'picks and shovels' play for the ongoing nuclear energy resurgence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Reviva to use the proceeds for its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia.</li><li>The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026.</li><li>Reviva implemented a 1-for-20 reverse share split on March 9.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plummeted more than 40% in pre-market trading on Thursday, after the company priced its public offering to raise about $10 million.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/RVPH">RVPH shares</a> would fall to a record low.<h2 class="st-heading-2">Offering At 20% Discount</h2>The offering consists of 6.67 million shares, as well as Series G and Series H warrants to purchase an equal number of shares, all priced at a combined $1.50 per share, for total gross proceeds of about $10 million. This represents a 20% discount on the stock’s closing price of $1.87 on Wednesday.Both warrants are immediately exercisable: Series G is valid for 5 years, and Series H expires in 12 months, the pharmaceutical company said. The offering is expected to close around March 20, 2026.Reviva said it plans to use the proceeds, along with existing cash, to support research and development, including its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia. Funds will also be used for working capital and general corporate needs.<h2 class="st-heading-2">Reviva To Begin A Second Phase 3 Trial In First Half Of 2026</h2>In January, the U.S. Food and Drug Administration (FDA) recommended conducting a second Phase 3 trial for its schizophrenia drug candidate to get additional efficacy and safety data before submitting a New Drug Application (NDA).The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026, subject to funding. Reviva said existing data showed strong efficacy across key symptoms of schizophrenia and a favorable safety profile, with over 900 patients treated so far.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market slump, retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier.Chatter was mixed. One user said the stock’s upside looks “amazing” and the company may require $60 to $70 million to complete the study.<stembedurl>https://stocktwits.com/Blaze321/message/647942525</stembedurl>Another user said there was “no chance” of raising the required funds.<stembedurl>https://stocktwits.com/Gropius/message/647911923</stembedurl>Reviva had announced a 1-for-20 reverse share split earlier this month, with the stock trading on an ex-split basis from March 9.For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did RVPH Stock Crash 40% In Pre-Market Today?

Reviva Pharmaceuticals Holdings company priced its $10 million offering at a 20% discount from Wednesday’s close.

Equity

The company priced its $10 million offering at a 20% discount from Wednesday’s close.

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

<ul class="summary-bullets"><li>FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database.</li><li>The company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026.</li><li>The company’s current estimates project that the trial cost will be around $60 million.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plunged more than 50% on Tuesday after the FDA called for an additional Phase 3 trial of the company’s schizophrenia treatment drug, dealing a significant setback to its regulatory timeline.In written feedback, the FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and further expand brilaroxazine’s safety database before submitting a new drug application (NDA).Subject to sufficient financing, the company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026. The study is expected to mirror the design of the completed RECOVER Phase 3 trial. The FDA also provided guidance on data analysis and presentation, as well as requirements for animal pharmacokinetics, human abuse potential, and renal and hepatic impairment studies.<h2 class="st-heading-2">Cost Of The Trial</h2>According to an SEC filing, the company’s current estimates project the trial cost at around $60 million, consisting of roughly $35 million in direct trial costs and approximately $24 million in general and administrative expenses.The FDA’s recommendation follows its review of two completed randomized, double-blind, placebo-controlled studies, including one Phase 2 and one Phase 3 trial with a one-year open-label extension. Across these studies, brilaroxazine demonstrated efficacy across major schizophrenia symptom domains, including negative symptoms, in 790 participants, Reviva added.At a meeting on December 18, Reviva shareholders approved the reverse stock split charter amendment, allowing the board to implement a 1-for-2 to 1-for-20 split at its discretion before Dec. 31, 2026. Companies generally use a reverse split to meet the $1.00 minimum bid price requirement under Nasdaq listing compliance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVPH">RVPH</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:919/97;" src="https://news.stocktwits-cdn.com/RVPH_png_6f1a479b84.webp" alt="RVPH.png" width="919" height="97"><figcaption>RVPH's Sentiment Meter and Message Volumes at 10:15 a.m. ET on Dec. 23, 2025 | Source: Stocktwits</figcaption></figure>One user opined on how the company could raise funds to cover the trial costs.<stembedurl>https://stocktwits.com/jgo1/message/639964998</stembedurl>Another user speculated about the trial timelines.<stembedurl>https://stocktwits.com/hawkeye45691/message/639962383</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spot-silver-crosses-70-an-ounce-for-the-first-time/cLep81RREuz">Spot Silver Crosses $70 An Ounce For The First Time</a> For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Reviva Pharmaceuticals Holdings Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

RVPH
Reviva Pharmaceuticals Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RVPH News

RVPHReviva Pharmaceuticals Holdings Inc.